<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03731910</url>
  </required_header>
  <id_info>
    <org_study_id>SNUH-1807-149-957</org_study_id>
    <nct_id>NCT03731910</nct_id>
  </id_info>
  <brief_title>Short-term MRI for Treatment Response Evaluation/Prediction of HCC Treated With TARE</brief_title>
  <official_title>Short Term Magnetic Resonance Imaging (MRI) for Treatment Response Evaluation and Prognosis Prediction in Patients With Hepatocellular Carcinoma (HCC) Treated With Transarterial Radioembolization (TARE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dongkook Lifesicence</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to investigate the value of early change at MRI in HCC treated with TARE, for
      evaluation/prediction of treatment response and prognosis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 11, 2018</start_date>
  <completion_date type="Anticipated">October 20, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 20, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment response mRECIST</measure>
    <time_frame>1 month after last MRI</time_frame>
    <description>treatment response using mRECIST</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor diffusion</measure>
    <time_frame>1 months after last MRI</time_frame>
    <description>measured with diffusion-weighted image sequence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor perfusion</measure>
    <time_frame>1 months after last MRI</time_frame>
    <description>measured with dynamic contrast-enhanced imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment response LI-RADS</measure>
    <time_frame>1 months after last MRI</time_frame>
    <description>treatment response using LI-RADSv 2018 treatment response category</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment response volumetric</measure>
    <time_frame>1 months after last MRI</time_frame>
    <description>treatment response using volumetric response criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression</measure>
    <time_frame>24 months after TARE</time_frame>
    <description>Time until to definite progression on follow-up images</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>HCC group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who are scheduled for TARE for HCC treatment. They undergo MRI three times- before, 1- and 2-week after TARE.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>MRI</intervention_name>
    <description>liver MRI using standard dose of extracellular agent. It includes dynamic contrast-enhanced MRI and diffusion weighted image.</description>
    <arm_group_label>HCC group</arm_group_label>
    <other_name>magnetic resonance imaging</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Intermediate or locally advanced HCC according to Hong Kong Liver Cancer guideline

          -  Scheduled for transarterial radioembolization (TARE)

          -  sign informed consent

        Exclusion Criteria:

          -  Any absolute or relative contra-indication of contrast-enhanced MRI

          -  History of other local treatment before TARE in 3 weeks
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeong Min Lee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hyun Hee Lee, RN</last_name>
    <phone>82-2-2072-4177</phone>
    <email>redlion55@naver.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jeong Hee Yoon, MD</last_name>
    <phone>82-2-2072-2584</phone>
    <email>jhjhry@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyun Hee Lee, RN</last_name>
      <phone>82-2-2072-4177</phone>
      <email>redlion55@naver.com</email>
    </contact>
    <contact_backup>
      <last_name>Jeong Hee Yoon, MD</last_name>
      <phone>82-2-2072-2584</phone>
      <email>jhjhry@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jeong Min Lee, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>November 4, 2018</study_first_submitted>
  <study_first_submitted_qc>November 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2018</study_first_posted>
  <last_update_submitted>July 16, 2019</last_update_submitted>
  <last_update_submitted_qc>July 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Jeong Min Lee</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>MRI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

